Sanofi
NASDAQ:SNYDrug Manufacturers - General
-$0.31 today
- Market cap
- $113.15B
- Beta
- 0.28
- P/E (TTM)
- 8.5
- EPS (TTM)
- $8.60
- Dividend yield
- 5.62%
Volume 2.32M
Average 2.78M
SNY Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
SanofiNASDAQ: SNY
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow turns negative
Q2 FY2026 financing cash flow was -€3.89B, compared with €0 a year earlier. Trailing-twelve-month financing cash flow was -€9.13B. Over 3 fiscal years it compounded at +16.7% a year.
Context
- Financing cash flow amounted to 19.8% of revenue in FY2025, up 6.8 pp from a year earlier.
- Financing cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near -€3.89B or moves back toward the trailing-twelve-month quarterly average of -€2.28B.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
EUR · from the cash flow
- Latest · FY2025
- (9.26B) EUR
- Year-over-year change
- -60.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.26B) | -60.7% |
| FY2024 | 2024-12-31 | (5.76B) | +28.4% |
| FY2023 | 2023-12-31 | (8.05B) | -38.3% |
| FY2022 | 2022-12-31 | (5.82B) | +17.5% |
| FY2021 | 2021-12-31 | (7.06B) | — |
Financing Cash Flow vs competitors
How SNY compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1442.5% is the 2nd highest of 11, against a peer median of +11.1%.
- Financing cash flow amounts to 18.7% of revenue for SNY, versus a peer median of 9.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 24.19B DKK | +8.3% | -18.1% | 7.3% | |
| LTM Jun 2026 | $11.71B USD | +40.7% | -15.2% | 23.8% | |
| LTM Jun 2026 | €9.13B EUR | +1442.5% | +16.7% | 18.7% | |
| LTM Jun 2026 | $8.4B USD | -53.8% | -11.4% | 13.2% | |
| LTM Jun 2026 | $6.17B USD | +141.8% | -40.5% | 9.3% | |
| LTM Sep 2026 | $5.39B USD | +9.1% | +3.4% | 8.7% | |
| LTM Jun 2026 | $4.65B USD | +13.0% | +6.2% | 15.3% | |
| LTM Jun 2026 | $4.13B USD | -65.2% | +39.1% | 10.8% | |
| LTM Jun 2026 | $2.61B USD | +2060.9% | -25.8% | 3.3% | |
| LTM Jun 2026 | £2.53B GBP | -29.6% | — | 7.6% | |
| LTM Jun 2026 | $472.2M USD | +102.8% | -10.1% | 0.8% | |
| Peer median (excluding SNY) | — | +11.1% | -11.4% | 9.0% | |
Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 6.22B | 7.97B | 5.06B | 5.5B | 5.57B |
| Depreciation & Amortization | 3.35B | 3.11B | 4.43B | 3.59B | 5.68B |
| Deferred Income Tax | (356M) | (529M) | (1.23B) | (802M) | (2.75B) |
| Stock-Based Compensation | 244M | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.41B | (794M) | 413M | (615M) | 2.03B |
| Accounts Receivables | 185M | (500M) | (472M) | (28M) | (1.36B) |
| Inventory | (357M) | (918M) | (866M) | (477M) | (44.02M) |
| Accounts Payables | 451M | 340M | 258M | 789M | 449.17M |
| Other Working Capital | 1.13B | 284M | 1.49B | (899M) | 2.98B |
| Other Non-Cash Items | (349M) | 771M | 1.59B | 1.42B | 1.61B |
| Operating Cash Flow | 10.52B | 10.53B | 10.26B | 9.08B | 12.13B |
| Capital Expenditures | (2.04B) | (2.1B) | (2.91B) | (3.2B) | (1.99B) |
| Acquisitions (Net) | (5.59B) | (1.34B) | (2.63B) | (2.52B) | 955.91M |
| Purchases of Investments | (311M) | (488M) | (134M) | 0 | (11.37B) |
| Sales of Investments | 718M | 0 | 0 | 0 | 0 |
| Other Investing Activities | (68M) | 1.86B | (533M) | 1.35B | 11.74B |
| Investing Cash Flow | (7.3B) | (2.08B) | (6.2B) | (4.41B) | (2.76B) |
| Debt Repayment | (2.8B) | (1.23B) | (3.14B) | (894M) | 2.07B |
| Common Stock Issued | 186M | 188M | 195M | 187M | 199.76M |
| Common Stock Repurchased | (382M) | (497M) | (593M) | (302M) | (5.68B) |
| Dividends Paid | (4.01B) | (4.17B) | (4.45B) | (4.7B) | (5.39B) |
| Other Financing Activities | (48M) | (111M) | (63M) | (50M) | (472.87M) |
| Financing Cash Flow | (7.06B) | (5.82B) | (8.05B) | (5.76B) | (9.26B) |
| Effect of Forex Changes | 15M | 8M | (32M) | (13M) | 862.16M |
| Net Change in Cash | (3.82B) | 2.64B | (4.03B) | (1.27B) | 970.51M |
| Free Cash Flow | 8.48B | 8.42B | 7.35B | 5.89B | 10.14B |
Sanofi
NASDAQ:SNY
Intrinsic Alpha fair value
Locked
Current Price
$47.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.